AELIS FARMA Aktie

 

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, announces the availability of the description of the share buyback program authorized by the Annual General Meeting of May 27, 2025. Pursuant to Article L. 22-10-62 et seq. of the French Commercial Code, the Combined General Meeting of shareholders authorized the Board of Directors, on May 27, 2025, in its 16th resolution, to implement a share buyback program of the Company, with powers to subdelegate in accordance with the law. In accordance with Article 241-3 of the General Regulation of the Autorité des Marchés Financiers (AMF), the description of the share buyback program is included in the Company's Universal Registration Document, which has been filed with the AMF on April 28, 2025, under number D.25-0314. This document is available on the Compan...

2024 has been marked by several significant events: The achievement of key milestones for the Company's two drug candidates: AEF0117: announcement of the results of the Phase 2b clinical study in cannabis use disorders AEF0217: announcement of results from the Phase 1/2 clinical study in the treatment of cognitive deficits in trisomy 21. These results confirm the safety and pharmacological activity of the new CB1-SSi class in humans. Expansion of the capabilities of the proprietary platform to intensify and accelerate the screening and identification of new CB1-SSi molecules. Solid cash position of €14 million as of December 31, 2024, strengthened by a fundraising in July 2024 and ensuring financial visibility until the end of 2026. BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its...

BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specializing in the development of treatments for brain and peripheral diseases involving the CB1 receptor, today announces its indicative financial calendar for the financial year 2025. Event Date of release* 2024 Annual Results Tuesday, April 1, 2025 Annual General Meeting Tuesday, May 27, 2025 2025 Half-Year Results Monday, September 22, 2025 (*) The press releases will be issued after the close of trading. Information may be subject to change. *** About AELIS FARMA Founded in Bordeaux in 2013, Aelis Farma is a biopharmaceutical company that is developing a new class of drugs, the Signaling Specific inhibitors of the CB1 receptor of the endocannabinoid system (CB1-SSi). CB1-SSi have been developed by Aelis Farma based on the discovery of a natural regulatory mechanism of CB1 hyperactivity made by the team led by Dr Pier Vincenzo Piazza, the Company's CEO, w...

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter morningstar.co.uk zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...

Um den gesamten Artikel unter morningstar.com zu lesen, klicken Sie bitte auf die Überschrift...